Insights on Drug Levels and Non-Sustained Viral Suppression With Long-Acting Cabotegravir and Rilpivirine Therapy

被引：0
作者：
Gutierrez, Felix [1 ,2 ,3 ]
Fernandez-Gonzalez, Marta [1 ,3 ]
Ledesma, Christian [1 ]
Losada-Echeberria, Maria [4 ]
Barrajon-Catalan, Enrique [4 ]
Masia, Mar [1 ,2 ,3 ]
机构：
[1] Hosp Gen Univ Elche, Infect Dis Unit, Elche, Spain
[2] Univ Miguel Hernandez, Dept Clin Med, Avda Univ S-N, Alicante 03202, Spain
[3] Inst Salud Carlos III, CIBERINFEC, Madrid, Spain
[4] Univ Miguel Hernandez, Inst Res Dev & Innovat Hlth Biotechnol Elche IDiBE, Elche, Spain
来源：
CLINICAL INFECTIOUS DISEASES | 2025年
关键词：
D O I：
10.1093/cid/ciae617
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Virological History Predicts Non-sustained Viral Suppression With Long-Acting Cabotegravir and Rilpivirine Therapy, Independent of Pharmacokinetic Parameters
    Gutierrez, Felix
    Fernandez-Gonzalez, Marta
    Ledesma, Christian
    Losada-Echeberria, Maria
    Barrajon-Catalan, Enrique
    Garcia-Abellan, Javier
    De Stefano, Daria
    Lopez, Leandro
    Bello-Perez, Melissa
    Padilla, Sergio
    Masia, Mar
    CLINICAL INFECTIOUS DISEASES, 2024, : 842 - 853
  • [2] Is Nonsustained Viral Suppression With Long-Acting Cabotegravir and Rilpivirine Really Independent of Drug Levels?
    Thoueille, Paul
    Marzolini, Catia
    Guidi, Monia
    Cavassini, Matthias
    Decosterd, Laurent A.
    CLINICAL INFECTIOUS DISEASES, 2025,
  • [3] Pharmacokinetics and Drug–Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine
    Daryl Hodge
    David J. Back
    Sara Gibbons
    Saye H. Khoo
    Catia Marzolini
    Clinical Pharmacokinetics, 2021, 60 : 835 - 853
  • [4] Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression
    Swindells, Susan
    Andrade-Villanueva, Jaime-Federico
    Richmond, Gary J.
    Rizzardini, Giuliano
    Baumgarten, Axel
    Masia, Mar
    Latiff, Gulam
    Pokrovsky, Vadim
    Bredeek, Fritz
    Smith, Graham
    Cahn, Pedro
    Kim, Yeon-Sook
    Ford, Susan L.
    Talarico, Christine L.
    Patel, Parul
    Chounta, Vasiliki
    Crauwels, Herta
    Parys, Wim
    Vanveggel, Simon
    Mrus, Joseph
    Huang, Jenny
    Harrington, Conn M.
    Hudson, Krischan J.
    Margolis, David A.
    Smith, Kimberly Y.
    Williams, Peter E.
    Spreen, William R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (12) : 1112 - 1123
  • [5] Pharmacokinetics and Drug-Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine
    Hodge, Daryl
    Back, David J.
    Gibbons, Sara
    Khoo, Saye H.
    Marzolini, Catia
    CLINICAL PHARMACOKINETICS, 2021, 60 (07) : 835 - 853
  • [6] The future of long-acting cabotegravir plus rilpivirine therapy: deeds and misconceptions
    Rusconi, Stefano
    Santoro, Maria M.
    Capetti, Amedeo F.
    Gianotti, Nicola
    Zazzi, Maurizio
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2022, 60 (03)
  • [7] Question and answers on long-acting therapy with cabotegravir and rilpivirine in people with HIV
    Taramasso, Lucia
    Bonora, Stefano
    Cingolani, Antonella
    Di Biagio, Antonio
    Gianotti, Nicola
    Guaraldi, Giovanni
    Lo Caputo, Sergio
    Madeddu, Giordano
    Maggi, Paolo
    Marchetti, Giulia
    Nozza, Silvia
    Rusconi, Stefano
    Maggiolo, Franco
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2025, 80 (03) : 610 - 623
  • [8] Implementing long-acting injectable cabotegravir and rilpivirine in Africa
    Orkin, Chloe
    Ring, Kyle
    LANCET INFECTIOUS DISEASES, 2024, 24 (10) : 1060 - 1061
  • [9] Expanded Insights From a Case Study on Long-Acting Injectable Cabotegravir and Rilpivirine in Pregnancy
    Ziemba, Lauren
    Ketchum, Rachel
    Brummel, Sean
    CLINICAL INFECTIOUS DISEASES, 2025,
  • [10] Virological rebound and low drug levels of unknown origin under long-acting Cabotegravir (CAB)/Rilpivirine (RPV)
    Ruff, F.
    Kalubi, M.
    Hampel, B.
    HIV MEDICINE, 2023, 24 : 783 - 784
12345